You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Prosolia, Inc. Topic: NIGMS
DESCRIPTION provided by applicant Most samples of chemical interest are complex mixtures making the usual combination of chromatography with mass spectrometry MS a natural choice However the increased demand for chemical analysis by mass spectrometry in many areas of science makes it imperative to increase efficiency of analysis by minimizing sample workup and overall analysis time which ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemiaSBC: MICROFLUIDIC INNOVATIONS, LLC Topic: 102
DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: SOLUBLE THERAPEUTICS, INC Topic: 100
DESCRIPTION provided by applicant The increasing output of new integral membrane protein IMP structures is partially due to the availability of an increasing number of chemical variables such as detergents detergent like molecules lipids and solubilizing stabilizing additives It is clear that specific combinations and concentrations of these different variables are often necessary to impr ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: Vibronix, Inc. Topic: 102
DESCRIPTION provided by applicant Prostate cancer PCa is the No killer among male cancer patients The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues This conventional diagnostic procedure is invasive missing cases of cancer due to small sampling volume Moreover it leads to an overtreatment of patients du ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: FasCure Therapeutics LLC Topic: NIAID
DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: NERX BIOSCIENCES, INC. Topic: NCI
DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: Biomedical Development Corporation Topic: 103
DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: Rimedion, Inc. Topic: NHLBI
DESCRIPTIONprovided by applicantIn this Phase II STTR application Rimedion seeks to commercialize a novel treatment for patients suffering from Fanconi anemia and request funding for a Phase I II clinical trialThe product will utilize a HIVbased lentiviral vector expressin the Fanconi anemia A proteinThe strong scientific support for this approached is strengthened by a successful Phase I STTRThe ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: iXpressGenes, Inc. Topic: 100
DESCRIPTION provided by applicant Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite techno ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: AEON IMAGING LLC Topic: W
DESCRIPTION provided by applicant Recently we found extensive remodeling of the microvasculature of the retina occurring in some diabetic patients much earlier than expected This provides the potential for novel biomarkers However the equipment is too expensive for most clinics and small practices These early retinal microvascular changes cannot be seen with routine clinical examination o ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health